Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,858,492
  • Shares Outstanding, K 57,915
  • Annual Sales, $ 36,500 K
  • Annual Income, $ 673,730 K
  • EBIT $ -440 M
  • EBITDA $ -449 M
  • 60-Month Beta 0.77
  • Price/Sales 50.52
  • Price/Cash Flow N/A
  • Price/Book 1.26

Options Overview Details

View History
  • Implied Volatility 62.21% ( -7.21%)
  • Historical Volatility 38.47%
  • IV Percentile 76%
  • IV Rank 44.67%
  • IV High 91.49% on 04/08/25
  • IV Low 38.58% on 05/21/25
  • Put/Call Vol Ratio 999.99
  • Today's Volume 432
  • Volume Avg (30-Day) 224
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 6,471
  • Open Int (30-Day) 7,066

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -1.74
  • Number of Estimates 5
  • High Estimate -1.67
  • Low Estimate -1.88
  • Prior Year -1.69
  • Growth Rate Est. (year over year) -2.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.27 +21.43%
on 05/09/25
33.69 -1.71%
on 06/02/25
+3.02 (+10.02%)
since 05/02/25
3-Month
23.42 +41.40%
on 04/09/25
35.70 -7.24%
on 03/03/25
-2.42 (-6.82%)
since 02/28/25
52-Week
23.42 +41.40%
on 04/09/25
62.58 -47.08%
on 11/11/24
-3.22 (-8.87%)
since 05/31/24

Most Recent Stories

More News
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

AGIO : 33.02 (+2.90%)
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

AGIO : 33.02 (+2.90%)
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

AGIO : 33.02 (+2.90%)
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates

Agios Pharmaceuticals AGIO incurred a loss of $1.55 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.80. In the year-ago quarter, the company had reported...

BEAM : 16.67 (+5.31%)
IMCR : 38.79 (+5.98%)
AGIO : 33.02 (+2.90%)
ADMA : 20.02 (+0.91%)
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

AGIO : 33.02 (+2.90%)
Agios Pharmaceuticals: Q1 Earnings Snapshot

Agios Pharmaceuticals: Q1 Earnings Snapshot

AGIO : 33.02 (+2.90%)
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

AGIO : 33.02 (+2.90%)
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

AGIO : 33.02 (+2.90%)
New Strong Sell Stocks for April 8th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Air France-KLM AFLYY is an airline company with core business is passenger transport, cargo transport, and aircraft maintenance...

AGIO : 33.02 (+2.90%)
AFLYY : 1.1200 (+1.82%)
ARLP : 26.19 (+0.60%)
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

AGIO : 33.02 (+2.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 35.02
2nd Resistance Point 33.75
1st Resistance Point 32.92
Last Price 33.02
1st Support Level 30.82
2nd Support Level 29.55
3rd Support Level 28.72

See More

52-Week High 62.58
Fibonacci 61.8% 47.62
Fibonacci 50% 43.00
Fibonacci 38.2% 38.38
Last Price 33.02
52-Week Low 23.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »